In the context of treating advanced HER2-negative gastric cancer, the combination of immune checkpoint inhibitors with chemotherapy has shown significant survival benefits in terms of overall survival (OS) and progression-free survival (PFS) (3). This evidence concerns the gene ERBB2 and gastric cancer.